Blueprint Medicines Touts Long-Term Drug Safety
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study of the drug AYVAKIT. The results show a sustained benefit and long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder. The company presented 12 datasets at the 2026 AAAAI Annual Meeting.
The U.S. Food and Drug Administration (FDA) approved AYVAKIT (avapritinib) for adults with indolent systemic mastocytosis (ISM) on May 22, 2023. This marked a significant shift in treatment, making it the first and only medicine approved to treat this rare blood disorder, moving beyond merely supportive care to a disease-modifying therapy. The approval was based on the double-blind, placebo-controlled Phase 2 PIONEER trial. In that study, patients taking AYVAKIT showed a statistically significant and clinically meaningful improvement in their total symptom scores at 24 weeks compared to those on placebo. AYVAKIT is a precision therapy designed to target the primary underlying cause of the disease. It potently and selectively inhibits KIT D816V, a genetic mutation that drives the abnormal proliferation of mast cells in about 95% of systemic mastocytosis cases. The PIONEER study enrolled 212 patients, with 141 receiving a 25 mg daily dose of AYVAKIT. The drug was well-tolerated, with 96% of patients in the AYVAKIT arm choosing to continue treatment in an open-label extension of the study. In a deal valued at approximately $9.5 billion, the French pharmaceutical giant Sanofi completed its acquisition of Blueprint Medicines in July 2025. The acquisition gives Sanofi control of AYVAKIT and strengthens its portfolio in rare immunological diseases. Looking ahead, the company is developing a next-generation treatment for systemic mastocytosis called elenestinib. This investigational drug is currently being evaluated in a Phase 2/3 clinical trial named HARBOR.
